GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
R

Regencell Bioscience Holdings RGC · USD

Health Care · US listing · 🇺🇸 United States

Compare

5.63

+6.74%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2026

Revenue

—

FY2017FY2026

Net income

−$11.7m

FY2017FY2026

Free cash flow

−$7.7m

FY2017FY2026

Shareholders' equity

$13.3m

FY2017FY2026

Income statement

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue————————$3.16bn$3.20bn
Research and development$1.3m$948,289$1.1m$1.6m$2.5m$438,323$386,230$228,223——
Operating income−$11.7m−$3.8m−$4.7m−$6.3m−$7.6m−$1.4m−$812,371−$390,990$271.7m$344.2m
Net income−$11.7m−$3.6m−$4.3m−$5.9m−$7.4m−$1.3m−$812,371−$390,990$112.3m$170.4m
Diluted earnings per share-0.02-0.01-0.01-0.01-0.02-0.00-0.00-0.000.230.03

Balance sheet

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Total assets$14.7m$5.8m$8.4m$12.6m$18.0m$340,134$514,018$243,307$2.84bn$2.65bn
Cash and short-term investments$14.2m$4.9m$8.0m$11.6m$16.4m$59,413$386,979$243,307$228.8m$246.5m
Total liabilities$1.4m$895,308$219,512$632,320$938,032$4.3m$3.2m$2.1m$3.70bn$3.48bn
Debt$295,811$544,415$85,741$463,669$771,255$3.7m$3.1m$2.1m$2.37bn$2.22bn
Shareholders' equity$13.3m$4.9m$8.2m$12.0m$17.1m−$4.0m−$2.7m−$1.8m−$855.8m−$838.9m
Shares outstanding495m494m494m494m494m493m380m380m495m5,967m

Cash flow

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations−$7.7m−$3.1m−$4.0m−$5.0m−$5.3m−$767,311−$726,573−$390,990$409.9m$410.5m
Capital spending—−$152,693−$5,376−$27,392−$780,876−$1−$117,837−$117,837−$250.4m−$214.9m
Free cash flow−$7.7m−$3.3m−$4.0m−$5.0m−$6.0m−$767,312−$844,410−$508,827$159.5m$195.6m
Dividends paid————————−$138.9m−$138.9m

Latest quarters

By quarter end

Sept 2026Mar 2026Sept 2025Dec 2024Sept 2024Jun 2024Mar 2024Dec 2023
Operating income−$6.4m−$5.3m−$1.8m−$2.0m−$988,918−$1,212−$1,212−$1,156
Net income−$6.4m−$5.3m−$1.7m−$1.9m−$926,807−$1,117−$1,117−$1,033
Diluted earnings per share-0.01-0.01-0.00-0.00-0.00-0.00-0.00-0.00
Cash from operations−$5.0m−$2.0m———−$2.0m—−$2.0m
Total assets$14.7m$3.0m$5.8m$7.5m$7.5m$8.4m$8.4m$10.5m
Cash and short-term investments$14.2m$2.4m$4.9m—$8.0m$8.0m$8.0m$4.8m
Debt$236,312$258,124$312,780—$119,614$59,807$59,807—
Shareholders' equity$13.3m$1.2m$4.9m$6.7m$6.7m$8.2m$8.2m$10.2m

Financial ratios

Data as of 30 Sept 2026

FY2025FY2024FY2023FY2022FY2021FY2020FY2018FY2017FY2016FY2015FY2014FY2013FY2010FY2009FY2008FY2007FY2006
Operating margin——————6.8%8.8%8.1%6.0%8.7%8.4%—————
Net margin——————3.6%5.3%4.9%3.5%5.2%5.1%—————
Return on equity-73.7%-52.3%-48.8%-43.5%33.7%30.6%———————————
Return on assets-62.3%-51.0%-46.5%-41.2%-395.9%-158.0%———————————
Free cash flow yield-0.1%-0.1%-0.2%-0.1%-0.0%-0.0%———————————
Revenue growth——————-1.1%2.2%4.6%-1.6%7.6%5.3%—————
Earnings growth-16.7%-26.7%-20.9%451.2%65.8%107.8%———————————
Current ratio7.39x41.92x19.15x28.46x0.02x0.12x———————————
Debt to equity0.06x0.01x0.04x0.02x-0.92x-1.16x———————————
Equity ratio84.4%97.4%95.3%94.7%-1175.3%-515.7%———————————
Interest coverage———-327.14x————————2.03x-0.02x4.40x0.14x0.29x
Buybacks as a share of market value-0.0%-0.0%0.0%-0.4%-29.7%0.0%———————————

Growth per year

Compound annual rate

3 years5 years10 years
Operating income23.2%53.4%—
Net income25.8%54.1%—

Valuation history

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021
Price to earnings-229.1-2897.2-9.3-14.5-30.5-191.2

Market value over time

31 Mar 2025 to 29 Sept 2026, in USD

$414.9m$3.07bn

Share price return

Finished calendar years

20252024202320222021
Return23724%-50%-67%10%158%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 38-for-1 split · 16 Jun 2025

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.